Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI tailors health coaching for older adults — will it boost muscle and movement?

NCT ID NCT07782320

Disease control Sponsor: Taipei Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 24, 2026 · Last updated Aug 25, 2026 · Updated 1 time

Summary

This study tests whether personalized health education generated by artificial intelligence can help older adults with sarcopenic obesity — a condition combining low muscle mass and excess fat. Participants receive daily AI-created text, images, voice, or video messages via social media chatbots for 12 weeks. The trial measures changes in physical activity, diet, muscle strength, and quality of life to see if this approach is feasible and effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Personalized AI-generated multimedia health education delivered via social media chatbots, including text, images, voice, and video materials
What this could lead to
If effective, this approach could offer an easy, enjoyable way to help older adults adopt healthier behaviors, potentially preventing or managing sarcopenic obesity.
What could go wrong
The trial is early and results may not show significant improvements. Also, the intervention relies on smartphone use, which may not suit all older adults.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 99 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. . Age: 60 years or older 2. . Smartphone ownership with internet connectivity 3. . Appendicular fat-free mass (AFFM) calculated by the equation: AFFM = 14.529 + (17.989 \* height)+ (0.1307 \* fat mass). The cut-off value corresponds to a residual ≤ 3.4 in the equation 4. . Ability to read, listen, and understand health education materials with normal cognitive function (MMSE score ≥ 25) and normal sensory function. Exclusion Criteria: 1. . Functional dependency 2. . Current residence in long-term care facilities or hospitals 3. . Presence of serious diagnosed diseases, disabilities, or mental health issues requiring medical treatment that might influence the study process.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sarcopenic obesity are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sarcopenic obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Taipei Medical University

    Taipei, 110, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.